Wilson Sonsini Goodrich & Rosati represented Insilico in the transaction. Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology...
Insilico Medicine’s License Agreement with Menarini Group
BioMap’s Collaboration with Sanofi
Wilson Sonsini Goodrich & Rosati advised BioMap on the transaction. BioMap announced a collaboration with Sanofi, to co-develop advanced AI modules for biotherapeutic drug discovery leveraging BioMap’s...
Insilico Medicine’s $80 Million Agreement with Exelixis
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Exelixis, Inc. and Insilico Medicine announced that they have entered into an exclusive license agreement granting Exelixis...
Arcellx’s $4 Billion Collaboration with Kite
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
Bruker’s Acquisition of Inscopix
Wilson Sonsini Goodrich & Rosati advised Inscopix on the deal. Bruker Corporation, a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions,...
Boston Scientific’s Acquisition of Obsidio
Wilson Sonsini Goodrich & Rosati advised Obsidio on the deal, while Latham & Watkins represented Boston Scientific Corporation. Boston Scientific Corporation announced the acquisition of Obsidio, Inc.,...
Apexigen’s Business Combination Agreement with Brookline Capital Acquisition Corp.
Wilson Sonsini advised Apexigen on the deal. Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology,...
ALX Oncology’s Acquisition of ScalmiBio
Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the deal. ALX Oncology Holdings Inc. (ALX Oncology), a clinical-stage immuno-oncology company, and ScalmiBio, Inc., announced that...
Arena Pharmaceuticals’ Strategic Collaboration with Aristea Therapeutics
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
Aristea’s $63 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
NuVasive’s Acquisition of Simplify Medical
Wilson Sonsini Goodrich & Rosati advised Simplify Medical on the deal. NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally...
WuXi AppTec’s Acquisition of OXGENE
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised WuXi AppTec on the deal. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in...